Cover Image

Epidemiology of Meropenem/Vaborbactam Resistance in KPC-Producing <i>Klebsiella pneumoniae</i> Causing Bloodstream Infections in Northern Italy, 2018

Meropenem/Vaborbactam (MEM-VAB) is a novel carbapenem- β-lactamase inhibitor active against KPC-producing Enterobacteria. Herein, we evaluate the incidence of meropenem/vaborbactam-resistance among KPC-producing <i>K. pneumoniae</i> (KPC-Kp) bloodstream infection in a large Italian hospi...

Full description

Saved in:

Bibliographic Details
Main Authors:	Paolo Gaibani (Author), Donatella Lombardo (Author), Linda Bussini (Author), Federica Bovo (Author), Beatrice Munari (Author), Maddalena Giannella (Author), Michele Bartoletti (Author), Pierluigi Viale (Author), Tiziana Lazzarotto (Author), Simone Ambretti (Author)
Format:	Book
Published:	MDPI AG, 2021-05-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Epidemiology and In Vitro Activity of Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam against <i>KPC</i>-Producing <i>K. pneumoniae</i> Collected from Bacteremic Patients, 2018 to 2020
by: Federica Bovo, et al.
Published: (2022)

Resistance to Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam in Gram-Negative MDR Bacilli: Molecular Mechanisms and Susceptibility Testing
by: Paolo Gaibani, et al.
Published: (2022)

Comparison of Broth Microdilution, Disk Diffusion and Strip Test Methods for Cefiderocol Antimicrobial Susceptibility Testing on KPC-Producing <i>Klebsiella pneumoniae</i>
by: Federica Bovo, et al.
Published: (2023)

Successful Treatment of Bacteremia and Ventilator-Associated Pneumonia Caused by KPC/OXA-48-like <i>Klebsiella pneumoniae</i> Co-Producer with a Continuous Infusion of High-Dose Meropenem Plus Fosfomycin Guided by Real-Time Therapeutic Drug Monitoring
by: Pier Giorgio Cojutti, et al.
Published: (2022)

Synergistic Meropenem/Vaborbactam Plus Fosfomycin Treatment of KPC Producing <i>K. pneumoniae</i> Septic Thrombosis Unresponsive to Ceftazidime/Avibactam: From the Bench to the Bedside
by: Alessandra Oliva, et al.
Published: (2021)

In Vitro Evaluation of Increasing Avibactam Concentrations on Ceftazidime Activity against Ceftazidime/Avibactam-Susceptible and Resistant KPC-Producing <i>Klebsiella pneumoniae</i> Clinical Isolates
by: Marta Palombo, et al.
Published: (2023)

Meropenem-Vaborbactam for the Treatment of Post-Neurosurgical Meningitis Caused by KPC Producer Klebsiella Pneumoniae: A Case Report and Review of the Literature
by: Leonardo Francesco Rezzonico, et al.
Published: (2024)

Pharmacokinetic/Pharmacodynamic Analysis of Continuous-Infusion Fosfomycin in Combination with Extended-Infusion Cefiderocol or Continuous-Infusion Ceftazidime-Avibactam in a Case Series of Difficult-to-Treat Resistant <i>Pseudomonas aeruginosa</i> Bloodstream Infections and/or Hospital-Acquired Pneumonia
by: Milo Gatti, et al.
Published: (2022)

Meropenem/Vaborbactam Plus Aztreonam as a Possible Treatment Strategy for Bloodstream Infections Caused by Ceftazidime/Avibactam-Resistant <i>Klebsiella pneumoniae</i>: A Retrospective Case Series and Literature Review
by: Alessandra Belati, et al.
Published: (2022)

Fast and Sensitive Method for Simultaneous Quantification of Meropenem and Vaborbactam in Human Plasma Microsamples by Liquid Chromatography-Tandem Mass Spectrometry for Therapeutic Drug Monitoring
by: Rossella Barone, et al.
Published: (2023)

Opportunistic infections in end stage liver disease
by: Michele Bartoletti, et al.
Published: (2018)

Comparative In Vitro Activity of Ceftazidime-Avibactam, Imipenem-Relebactam, and Meropenem-Vaborbactam against Carbapenem-Resistant Clinical Isolates of <i>Klebsiella pneumoniae</i> and <i>Pseudomonas aeruginosa</i>
by: Anthony Sophonsri, et al.
Published: (2024)

Meropenem/Vaborbactam-A Mechanistic Review for Insight into Future Development of Combinational Therapies
by: Trae Hillyer, et al.
Published: (2024)

In Vitro and In Vivo Synergism of Fosfomycin in Combination with Meropenem or Polymyxin B against KPC-2-Producing <i>Klebsiella pneumoniae</i> Clinical Isolates
by: Aghata Cardoso da Silva Ribeiro, et al.
Published: (2023)

Ceftazidime/Avibactam and Meropenem/Vaborbactam for the Management of Enterobacterales Infections: A Narrative Review, Clinical Considerations, and Expert Opinion
by: Andrea Marino, et al.
Published: (2023)

Meropenem/Vaborbactam: β-Lactam/β-Lactamase Inhibitor Combination, the Future in Eradicating Multidrug Resistance
by: Anna Duda-Madej, et al.
Published: (2023)

Effect of Ceftaroline, Ceftazidime/Avibactam, Ceftolozane/Tazobactam, and Meropenem/Vaborbactam on Establishment of Colonization by Vancomycin-Resistant Enterococci and Klebsiella pneumoniae in Mice
by: Bryan Hausman, et al.
Published: (2024)

Neonatal Bloodstream Infection with Ceftazidime-Avibactam-Resistant <i>bla</i><sub>KPC-2</sub>-Producing <i>Klebsiella pneumoniae</i> Carrying <i>bla</i><sub>VEB-25</sub>
by: Charalampos Zarras, et al.
Published: (2023)

Impact of Maximizing Css/MIC Ratio on Efficacy of Continuous Infusion Meropenem Against Documented Gram-Negative Infections in Critically Ill Patients and Population Pharmacokinetic/Pharmacodynamic Analysis to Support Treatment Optimization
by: Pier Giorgio Cojutti, et al.
Published: (2021)

In Vitro Activity of Imipenem-Relebactam, Meropenem-Vaborbactam, Ceftazidime-Avibactam and Comparators on Carbapenem-Resistant Non-Carbapenemase-Producing Enterobacterales
by: Rémy A. Bonnin, et al.
Published: (2023)

Meropenem MICs at Standard and High Inocula and Mutant Prevention Concentration Inter-Relations: Comparative Study with Non-Carbapenemase-Producing and OXA-48-, KPC- and NDM-Producing <i>Klebsiella pneumoniae</i>
by: Maria V. Golikova, et al.
Published: (2023)

A Proof of Concept of the Usefulness of a TDM-Guided Strategy for Optimizing Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Ampicillin-Based Regimens in a Case Series of Patients with Enterococcal Bloodstream Infections and/or Endocarditis
by: Milo Gatti, et al.
Published: (2022)

Bloodstream Infections caused by Klebsiella pneumoniae and Serratia marcescens isolates co-harboring NDM-1 and KPC-2
by: Taniela Bes, et al.
Published: (2021)

Prompt and Appropriate Antimicrobial Therapy Improves Outcomes of NDM-Producing and KPC-Producing <i>Klebsiella pneumoniae</i> Bloodstream Infections in Patients Hospitalized for COVID-19: A Comparative Retrospective Case-Series
by: Davide Fiore Bavaro, et al.
Published: (2022)

Fluorescence Microscopy: Determination of Meropenem Activity against <i>Klebsiella pneumoniae</i>
by: Kamilla N. Alieva, et al.
Published: (2023)

The <i>Klebsiella pneumoniae</i> carbapenemase (KPC) β-Lactamase Has Evolved in Response to Ceftazidime Avibactam
by: Sona Garsevanyan, et al.
Published: (2023)

Detection of KPC-216, a Novel KPC-3 Variant, in a Clinical Isolate of <i>Klebsiella pneumoniae</i> ST101 Co-Resistant to Ceftazidime-Avibactam and Cefiderocol
by: Maria Giufrè, et al.
Published: (2024)

Synergistic Activity of Temocillin and Fosfomycin Combination against KPC-Producing <i>Klebsiella pneumoniae</i> Clinical Isolates
by: Venera Costantino, et al.
Published: (2024)

Two Distinct Genotypes of KPC-2-Producing <i>Klebsiella pneumoniae</i> Isolates from South Korea
by: Jee Hong Kim, et al.
Published: (2021)

Carbapenemase Producing <i>Klebsiella pneumoniae</i> (KPC): What Is the Best MALDI-TOF MS Detection Method
by: Lukáš Hleba, et al.
Published: (2021)

Poor Sensitivity of the MALDI Biotyper<sup>®</sup> MBT Subtyping Module for Detection of <i>Klebsiella pneumoniae</i> Carbapenemase (KPC) in <i>Klebsiella</i> Species
by: Luz Cuello, et al.
Published: (2023)

Characterization of <i>bla</i><sub>KPC-2</sub>-Carrying Plasmid pR31-KPC from a <i>Pseudomonas aeruginosa</i> Strain Isolated in China
by: Min Yuan, et al.
Published: (2021)

Resistance to Ceftazidime/Avibactam in <i>Klebsiella pneumoniae</i> KPC-Producing Isolates: A Real-Life Observational Study
by: Laura Campogiani, et al.
Published: (2023)

Ceftazidime-Avibactam in Combination with Imipenem as Salvage Therapy for ST11 KPC-33-Producing <i>Klebsiella pneumoniae</i>
by: Li Ding, et al.
Published: (2022)

First case report of a vertebral osteomyelitis caused by carbapenem-resistant Enterobacter cloacae treated with imipenem/cilastatin/relebactam prolonged infusion then meropenem/vaborbactam in continuous infusion
by: Paul Laffont-Lozes, et al.
Published: (2024)

Colistin, Meropenem-Vaborbactam, Imipenem-Relebactam, and Eravacycline Testing in Carbapenem-Resistant Gram-Negative Rods: A Comparative Evaluation of Broth Microdilution, Gradient Test, and VITEK 2
by: Patrick Forstner, et al.
Published: (2024)

Does Cytokine-Release Syndrome Induced by CAR T-Cell Treatment Have an Impact on the Pharmacokinetics of Meropenem and Piperacillin/Tazobactam in Patients with Hematological Malignancies? Findings from an Observational Case-Control Study
by: Chun Liu, et al.
Published: (2023)

Evaluation of the Ability to Form Biofilms in KPC-Producing and ESBL-Producing <i>Klebsiella pneumoniae</i> Isolated from Clinical Samples
by: Carolina Sabença, et al.
Published: (2023)

Complete Genome Sequences of <i>Klebsiella michiganensis</i> and <i>Citrobacter farmeri</i>, KPC-2-Producers Serially Isolated from a Single Patient
by: Jehane Y. Abed, et al.
Published: (2021)

Clinical Outcomes and Safety of Meropenem-Colistin versus Meropenem-Tigecycline in Patients with Carbapenem-Resistant <i>Acinetobacter baumannii</i> Pneumonia
by: Jae-Min Park, et al.
Published: (2021)